Ipamorelin vs MK-677: GH Peptide Showdown

Ipamorelin and MK-677 (ibutamoren) both raise growth hormone and IGF-1 by acting on the same ghrelin receptor, but they are not interchangeable. Ipamorelin is an injectable peptide that works in short, selective bursts, while MK-677 is an oral, non-peptide molecule with a long, sustained effect and a notable appetite kick. Neither is FDA-approved, both are banned in sport, and which one (if either) fits a given person is a clinical call, not a forum poll.

What is the regulatory status of ipamorelin and MK-677?

Before anything else, the framing matters. Neither ipamorelin nor MK-677 is approved by the U.S. Food and Drug Administration (FDA) for any indication. Both are sold as research chemicals rather than as licensed medicines.

Both are also prohibited by the World Anti-Doping Agency (WADA) under category S2 at all times, in and out of competition, on the 2026 Prohibited List. If you compete in a tested sport, either one can end your eligibility.

Every dose figure in this article is a range reported by the community and the published literature, not a recommendation. No validated dose exists for either compound, and a licensed provider sets any dose. Legitimate prescription pathways do exist (some compounding pharmacies and real prescribers), but that is a conversation to have with a clinician, not a shopping list.

How do GH secretagogues work (briefly)?

A few definitions up front, because the rest of the article leans on them. Growth hormone (GH) is a hormone released by the pituitary gland that influences tissue growth, body composition, and metabolism. Much of its downstream effect runs through IGF-1 (insulin-like growth factor 1), a hormone the liver makes in response to GH that acts as a longer-lasting messenger.

A secretagogue is simply something that prompts a gland to secrete a hormone. A growth-hormone secretagogue prompts your own pituitary to release more GH, rather than supplying GH directly the way injected recombinant human GH does.

Both ipamorelin and MK-677 are ghrelin mimetics, meaning they imitate ghrelin, the so-called hunger hormone. They do this by binding the GHSR (growth-hormone secretagogue receptor, also called the ghrelin receptor), specifically the GHSR-1a subtype. Activating that receptor triggers GH release. For the broader category and how these compounds compare to other approaches, see our overview of growth-hormone peptides explained.

One more term worth defining: pulsatile release. Your body normally secretes GH in pulses (bursts), not as a flat, constant level. That detail matters later, because the two compounds affect that rhythm differently.

Ipamorelin: what is it?

Ipamorelin is a synthetic pentapeptide (a small chain of five amino acids) that acts as a ghrelin mimetic and GH secretagogue. It is injectable, given subcutaneously (under the skin), and it is short-acting, producing a relatively brief pulse of GH after each dose.

Its main claim to attention is selectivity. Ipamorelin is often described as the most selective GH secretagogue: it stimulates GH with minimal effect on cortisol, prolactin, or ACTH (adrenocorticotropic hormone). That distinguishes it from older secretagogues like GHRP-2 and GHRP-6, which tend to spike appetite and cortisol along with GH.

The evidence base, though, is thin where it counts. Most of what supports ipamorelin is preclinical, meaning animal and lab studies, including GH and IGF-1 elevation and some bone-density effects. Human data are extremely sparse, and there are no published Phase III trials. It is used in some compounding-pharmacy protocols without substantial randomized controlled trial (RCT) support.

The regulatory picture got tougher recently. The FDA's Pharmacy Compounding Advisory Committee (PCAC) voted against ipamorelin at both its October and December 2024 meetings, meaning it was not cleared for 503A compounding. Ipamorelin is also prohibited under WADA category S2 at all times. In practice, ipamorelin is frequently combined with CJC-1295, a GHRH (growth-hormone-releasing hormone) analog, to hit GH release through two pathways at once. Our ipamorelin guide goes deeper on that stacking logic.

As for dosing, community and literature reports often discuss ipamorelin around 200 to 300 mcg per injection. Treat that as a description of what people report, not a target: no validated dose exists, and a provider sets any dose.

MK-677 (ibutamoren): what is it?

MK-677, also called ibutamoren, is not a peptide. It is a non-peptide, orally bioavailable small molecule that mimics ghrelin and binds the GHSR-1a (ghrelin) receptor, raising GH and IGF-1. The headline practical difference is that it is orally active: a pill, no injection.

Its effect profile differs from ipamorelin's in two important ways. First, MK-677 is long-acting, producing a sustained effect that raises pulsatile GH while also driving a more continuous elevation in IGF-1. Second, because it mimics ghrelin, it stimulates appetite significantly, which can be a feature for some clinical goals and a problem for others.

MK-677 also has more published human data than most compounds in this category, which is why it anchors much of the evidence discussion. The best available trial is Nass et al. 2008, published in Annals of Internal Medicine, which gave 25 mg per day for 12 months to 65 healthy older adults. The results are worth stating plainly: lean mass rose about 1.1 kg and body weight rose about 1.5 kg, but fat was gained too, and there was no improvement in muscle strength or functional outcomes.

The metabolic findings in that same trial are the catch. Fasting glucose rose by roughly 5 mg/dL, and insulin sensitivity worsened. MK-677 has also been investigated in cancer cachexia (severe wasting) and hip-fracture recovery, with mixed functional outcomes and an investigational status only.

On status: MK-677 is not FDA-approved (it previously held investigational new drug, or IND, status). The FDA has explicitly warned that it is not legal as a dietary supplement ingredient, and it has turned up in adulterated supplements. It is prohibited under WADA category S2 at all times. Community and literature reports commonly discuss MK-677 around 10 to 25 mg per day orally, but again, no validated dose exists, and a provider sets any dose. Our MK-677 (ibutamoren) guide covers the details.

How do ipamorelin and MK-677 compare side by side?

Property	Ipamorelin	MK-677 (ibutamoren)
Type / route	Injectable pentapeptide, given subcutaneously	Oral, non-peptide small molecule
Mechanism	GHSR (ghrelin receptor) agonist, delivered by injection	GHSR-1a (ghrelin receptor) agonist, taken orally
Duration / half-life	Short-acting, brief GH pulse per dose	Long, sustained effect
Human evidence	Sparse; primarily preclinical; no Phase III trials	More extensive; best trial is Nass et al. 2008 (Annals of Internal Medicine)
Appetite effect	Reported minimal; among the more selective secretagogues	Significant increase (ghrelin mimicry)
Metabolic effects	Less characterized in humans	Raised fasting glucose (about +5 mg/dL) and worsened insulin sensitivity in Nass 2008
Water retention	Less commonly reported	Reported
Convenience	Subcutaneous injection	Oral pill
Status	Not FDA-approved; PCAC voted against it Oct/Dec 2024 (not cleared for 503A compounding)	Not FDA-approved; FDA warns it is not a legal dietary supplement ingredient
WADA	Prohibited (S2) at all times	Prohibited (S2) at all times

Side-by-side: convenience vs consequences?

The cleanest way to think about this pairing is a trade. MK-677 offers oral convenience, and that is genuinely appealing if needles are a dealbreaker. But that convenience comes attached to documented metabolic side effects: in the best available human trial, it raised fasting glucose, worsened insulin sensitivity, increased appetite, and added body weight that included fat.

Ipamorelin offers the opposite profile. Its selectivity is the selling point: it raises GH with reportedly minimal effect on cortisol, prolactin, ACTH, or appetite. But that comes at the cost of an injection and, more importantly, very thin human data. You are trading documented downsides for documented uncertainty.

Neither trade is obviously better. The point is that "oral and easy" and "selective and clean" both have an asterisk, and pretending otherwise is how people talk themselves into a compound their provider would have flagged.

What does the evidence actually show (and not show)?

The established part is narrow. Both compounds raise GH and IGF-1; that mechanism is real and reasonably well documented, more so for MK-677 in humans than for ipamorelin. What is far weaker is the leap from "raises GH/IGF-1" to "improves how your body actually looks and performs."

MK-677 is the cautionary example. In Nass 2008, twelve months of daily use raised lean mass but produced no improvement in muscle strength or functional outcomes, while also adding fat and worsening glucose handling. Higher hormone numbers did not translate into stronger, more capable people in that trial.

Ipamorelin's gap is different but no smaller: its body-composition story rests mostly on animal data, with human evidence too sparse to support confident real-world claims. For context, the only FDA-approved GH-axis peptide is tesamorelin (for HIV-associated lipodystrophy), which is neither of the two compounds here. That contrast is worth keeping in view: approval requires a level of evidence neither ipamorelin nor MK-677 has reached.

What are the shared safety considerations?

Both compounds share a class-wide theoretical concern: raising IGF-1 could, in principle, affect pre-existing cancers, because IGF-1 is a growth signal. This is why careful providers screen for malignancy history before considering anything in this category. It is a reason, not a scare tactic, but it is a real reason.

Then there is the gray-market problem. Because both are sold as research chemicals rather than approved medicines, sourcing and purity are genuine risks: what is on the label is not guaranteed to be what is in the vial or capsule, and the FDA has documented MK-677 turning up in adulterated supplements.

Add to that the absence of long-term human safety data for either compound, and the WADA bans for anyone who competes, and the case for provider involvement is hard to argue with. A clinician can screen, monitor labs, and weigh whether any of this makes sense for a specific person, which is something no article and no forum can do.

What should you ask a provider?

If you are seriously considering either compound, these are reasonable questions to bring to a licensed clinician:

• Given my goals, does an injectable (ipamorelin) or oral (MK-677) route make more sense, and why?
• If MK-677, how will we monitor fasting glucose and insulin sensitivity over time?
• What malignancy screening should happen first, given the IGF-1 concern?
• What is the current FDA and WADA status of each compound today?
• Realistically, what am I signing up for when there is no Phase III data and no approval behind either of these?

Where does Myo fit?

Comparing two GH compounds in practice is not a one-time decision; it means watching body composition and side effects over weeks. Myo logs both an injectable and an oral on their own schedules and trends the outcomes side by side, so a real provider-directed comparison is grounded in your data rather than your memory.

That matters specifically here. Myo separates fat-versus-lean trends, which is directly relevant to MK-677's reported fat gain and water retention, and it logs side effects and labs in a form you can bring to a provider for review. The proven muscle drivers remain training and protein, not any secretagogue, which is why pairing tracking with resistance training on a GLP-1 tends to do more for body composition than chasing GH numbers.

To be clear about what Myo is: it is a tracking and education tool. It does not prescribe, it does not source, and it does not replace a clinician. It helps you and your provider see what is actually happening.

The bottom line: ipamorelin and MK-677 both raise GH and IGF-1 through the ghrelin receptor, but ipamorelin is a short-acting, selective injectable with thin human data, while MK-677 is a convenient oral compound whose best trial showed real metabolic downsides and no strength benefit. Neither is FDA-approved, both are WADA-banned at all times, and the reported doses here are conventions, not recommendations. The right move, if any, is a provider conversation, not a self-directed experiment.

References

• Nass R, Pezzoli SS, Oliveri MC, et al. (2008). "Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial." Annals of Internal Medicine.
• FDA Pharmacy Compounding Advisory Committee Briefing Document. https://www.fda.gov/media/183819/download
• Lexology, FDA 503A Peptide Update. https://www.lexology.com/library/detail.aspx?g=2e55b76a-3173-4e04-beda-bf021202f18d
• WADA 2026 Prohibited List. https://www.wada-ama.org/en/prohibited-list
• Operation Supplement Safety (OPSS), MK-677 / ibutamoren. https://www.opss.org/article/performance-enhancing-substance-mk-677-ibutamoren